Anmelden Kostenlos registrieren

Akari Therapeutics Plc Institutionelles Eigentum

Was ist das Institutionelles Eigentum von Akari Therapeutics Plc?

Institutionelles Eigentum von Akari Therapeutics Plc ist 2.82%

Was ist die Definition von Institutionelles Eigentum?



Institutionelles Eigentum ist der Betrag der verfügbaren Aktien eines Unternehmens, das sich im Besitz von Investmentfonds oder Pensionskassen, Versicherungsgesellschaften, Wertpapierfirmen, Stiftungen oder anderen großen Körperschaften befindet, die Fonds für Dritte verwalten.

Given the considerable sums of money that institutions invest, it is not surprising that they tend to be much more knowledgeable than the average investor when it comes to the companies and industries in which they have invested.

Institutional portfolio managers often meet personally with a company's top executives, and in many cases the research they conduct is further supported by equity analysts who evaluate prospective companies and industries in great depth before making specific investment recommendations.

Institutionelles Eigentum von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Akari Therapeutics Plc

Was macht Akari Therapeutics Plc?

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Unternehmen mit institutionelles eigentum ähnlich Akari Therapeutics Plc